Trinity Biotech vs. Calypte & Osur & other Comp.
Seite 1 von 1 Neuester Beitrag: 17.07.05 19:34 | ||||
Eröffnet am: | 16.07.05 19:44 | von: Brokersince1. | Anzahl Beiträge: | 4 |
Neuester Beitrag: | 17.07.05 19:34 | von: Brokersince1. | Leser gesamt: | 2.554 |
Forum: | Hot-Stocks | Leser heute: | 1 | |
Bewertet mit: | ||||
Dieser Thread wurde Spez. für meinen Gefährten Joelü erstellt, da er selbst nicht in der Lage war einst zu erstellen....
Trinity Biotech Announces Donation of $1,000,000 of HIV Rapid Tests on National HIV Testing Day
Monday June 27, 9:05 am ET
DUBLIN, Ireland, June 27 /PRNewswire-FirstCall/ -- In recognition of National HIV Testing Day, Trinity Biotech plc (NASDAQ: TRIBD, ISE: TRIB.I) announced today that it will make a donation to the value of US$1m of their Uni-Gold(TM) Recombigen® HIV Rapid tests to community based organizations (CBO's) and public health facilities in the US in an effort to expand the availability of rapid HIV testing programmes.
The company will distribute the Uni-Gold Rapid HIV tests over the next six months to qualifying CBO's and public health facilities. Applications should be made through Trinity's corporate website: (www.trinitybiotech.com).
Trinity's Uni-Gold Recombigen HIV test is the only rapid test available in the United States which is both CLIA waived for venous and fingerstick whole blood use, and has FDA approval for use with serum, plasma, and whole blood. Similarly, it is the only CLIA waived product which can provide a result in as quickly as 10 minutes. The Uni-Gold HIV product has a demonstrated sensitivity and specificity of 100% and 99.7% respectively.
The CLIA waived status of the product makes it suitable for use in many publicly sponsored outreach settings, such as STD and HIV clinics, where workers and volunteers can perform the test without formal medical training. More information in regard to the Uni-Gold Recombigen HIV test can be found at www.unigoldhiv.com.
"We are delighted to help increase the number of Rapid HIV tests being performed in the United States through this donation of Uni-Gold Recombigen HIV Rapid tests, said Ronan O'Caoimh, Trinity Biotech CEO. "We are particularly pleased to do so on National HIV Testing Day and we hope that this donation will help the ongoing fight against HIV/AIDS. This donation is accessible to community based groups and public health facilities of all sizes and applications should be made though our website. An objective review panel consisting of members from NAPWA (National Association of People with AIDS) and NASTAD (National Alliance of State and Territorial AIDS Directors) will evaluate all completed applications, and a decision will be made on a needs based analysis."
As part of this donation, Trinity has worked with NAPWA to provide several community based organizations a total of 15,000 Uni-Gold Recombigen HIV tests which will be used for testing on National HIV Testing Day. These organizations include the Metropolitan Atlanta Outreach Association of Georgia and the Minority AIDS Project of Los Angeles California.
National HIV Testing Day (NHTD) is an annual campaign organized by NAPWA to encourage at-risk individuals to receive voluntary HIV counseling and testing. NAPWA distributes campaign kits to community groups and health departments of all sizes to help create NHTD campaigns and events targeting their local communities.
Trinity Biotech develops, acquires, manufactures and markets diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. The broad line of over 500 test kits are used to detect infectious diseases, sexually transmitted diseases, blood coagulation disorders, and autoimmune diseases. Trinity is also a significant provider of raw materials to the life science industry. Trinity Biotech sells worldwide in 78 countries through its own sales force and a network of international distributors and strategic partners. For further information please see the company's website: www.trinitybiotech.com.
Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialization and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.
--------------------------------------------------
Source: Trinity Biotech plc
Gruß
C.O
Ich hoffe es gefällt dir ...
Jetzt kannst du endlich deine Fachkenntnisse hier mit uns teilen...
Gruß
C.O